- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Nanjing King-Friend Biochemical PharmaceuticalLtd
Market Cap: CN¥15.2b
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
603707
CN¥9.48
7D
-1.3%
1Y
-25.5%
Pacific Shuanglin Bio-pharmacy
Market Cap: CN¥13.5b
Engages in research, development, production, and sales of blood products in China and internationally.
000403
CN¥14.18
7D
-2.1%
1Y
-15.0%